In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
HIGHLIGHTS
EVENTS
Kedrion keeps Hemophilia therapy debate flowing in Latin America
A recent CLAHT Congress symposium restates current and future role of replacement therapy
read moreCORPORATE
FSI SGR enters Kedrion share capital
The company continues with its growth and development strategy
read more-
EVENTS - 15-11-2019
Kedrion keeps Hemophilia therapy debate flowing in Latin America
A recent CLAHT Congress symposium restates current and future role of replacement therapy
read more -
CORPORATE - 16-10-2019
FSI SGR enters Kedrion share capital
The company continues with its growth and development strategy
read more -
CORPORATE - 04-10-2019
Kedrion submits to FDA for Manufacture of RhoGAM/MICRhoGAM in Melville, NY
read more -
EVENTS - 30-09-2019
Kedrion reaffirms its commitment for the global eradication of Rh disease
A worldwide initiative for maternal and fetal health launches in Florence, Italy
read more
Pages
For more information please contact: pressoffice@kedrion.com
Where 